Swiss clinical-stage radiopharmaceutical company Nuclidium completed a Series B financing round, raising CHF 79 million (EUR 84 million). Vischer advised Nuclidium throughout the operation, while Walder Wyss advised Angelini Ventures, Kurma Partners and Wellington Partners, in connection
Search Results for: vischer
Walder Wyss advised Energie 360° on its acquisition of Move Mobility from VISCHER acted as legal counsel to Primeo Energie, Groupe E and ewb. In connection with the deal Vischer advised the selling parties .Headquartered in
Vischer advised IT services and data center solutions specialist synaforce Group throughout its acquisition of ServerBase, a Swiss cloud platform based in Bachenbülach in the Canton of Zurich. The Vischer team Partner Jürg
Bratschi appointed Janusz Marty as a partner in Zurich, effective July 1st, 2025. He moves from Burckhardt. The profile A specialist across corporate and contract law, Janusz Marty regularly advises founders, investors and companies on financing
Snyck completed its acquisition Invariant labs, an AI security research company and spin-off of ETH Zurich based in Zurich. In connection with the deal, Wenger Vieli advised the shareolders of the selling part, while Vischer
Vischer advised Easternmed Real Estate Capital in its acquisition of a new prime commercial property in Geneva. The building in question is home to a hotel residence. The company Headquartered in Nicosia and listed with
Welcome to “signed sealed weekend”, our inside track on what’s happening in the Swiss legal market. Without further ado, let’s go through our news highlights of the week. In January 2025, Laurent Killias (pictured
Walder Wyss advised the Jacobs Foundation, an organization supporting child development and evidence-based education, as well as professional investment firm Jacobs Holding, in their transition from an intertwined setup to two independent institutions. The context
Vischer advised Swissroc Asset Management in connection with Swissroc Industrial Opportunities’ acquisition of a 4,200 m² light industrial building in the commune of Thônex (Geneva) from a professional investor. The 1991 building sits within the industrial
Vischer advised Mosanna Therapeutics in connection with its USD 80m Series A funding round. Headquartered in Basel, Switzerland, the clinical-stage biotech company, is working on a nighttime nasal spray to treat obstructive sleep apnea (OSA).
